Multiple switching between the biosimilar adalimumab PF-06410293 and reference adalimumab in patients with active rheumatoid arthritis: a phase 3, open-label, randomised, parallel-group study

Multiple switching between the biosimilar adalimumab PF-06410293 and reference adalimumab in patients with active rheumatoid arthritis: a phase 3, open-label, randomised, parallel-group study https://www.thelancet.com/journals/lanrhe/article/PIIS2665-9913(23)00161-3/fulltext?dgcid=hubspot_update_feature_updatealerts_lanrhe&utm_campaign=update-lanrhe&utm_medium=email&_hsmi=272897500&_hsenc=p2ANqtz-_Ply1rHcYvlAm3UvVI9dsTCjuc94ksBsE_DdW6LLLubgHc6wW_3ED-_TqF33QihJ8mpeuCYPXBxIp4n8lqkHwveVZrwg&utm_content=272625135&utm_source=hs_email